Clinical trials: SARS-COV 2
Disease Caused by Severe Acute Respiratory Syndrome Coronavirus 2 (Disorder)
A Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of Inhaled MBS-COV (SNS812) in Healthy Participants
A Phase I, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of Inhaled MBS-COV in Healthy Participants
- Trial name
- NCT05677893
- Testing
- MBS-COV
- Where
- United States
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Oneness Biotech Co., Ltd.
COVID-19, Vaccine-Preventable Diseases
The Efficacy of the 2023-2024 Updated COVID-19 Vaccines Against COVID-19 Infection
The purpose of this research study is to find out how well two different 2023-2024 updated COVID-19 vaccines protect people from COVID-19 (the disease caused by the SARS-CoV-2 virus), and to determine if getting a 2023-2024…
- Conditions
- COVID-19, Vaccine-Preventable Diseases, SARS CoV 2 Infection, Upper Respiratory Tract Infection
- Trial name
- BEEHIVE (NCT06065176)
- Testing
- Novavax COVID-19 vaccine (2023-2024 formula XBB containing), Pfizer COVID-19 mRNA vaccine (2023-2024 formula XBB containing)
- Where
- United States
- Volunteers
- 1,188 people, healthy volunteers welcome
- Sponsor
- Sarang K. Yoon, DO, MOH
Convalescent Plasma, COVID-19
Efficacy and Safety of COVID-19 Convalescent Plasma
Administration of convalescent plasma obtained from donors with prior documented SARS-CoV-2 infection
- Conditions
- Convalescent Plasma, COVID-19, SARS-CoV 2
- Trial name
- NCT04397523
- Testing
- anti-SARS-CoV-2 convalescent plasma
- Where
- North Macedonia
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Institute for Transfusion Medicine of RNM
COVID, SARS-CoV 2
Seroepidemiological Study of SARS-CoV-2 (COVID-19) Infection in Population Subgroups in the State of São Paulo
Seroepidemiological Study of SARS-CoV-2 Infection in Population Subgroups in the State of São Paulo
- Trial name
- NCT04408014
- Testing
- Serological test, Nasopharyngeal Swab, Oropharyngeal Swab
- Where
- Brazil
- Volunteers
- 18,901 people, healthy volunteers welcome
- Sponsor
- Butantan Institute
COVID-19 Pandemic, Immunogenicity
Safety and Immunogenicity of Omicron Variant-Matched Vaccine Booster in Adults
Under protocol versions 1.01-1.06: The five recently emerged SARS-CoV2 variants that were designated as VOCs are the Alpha variant, Beta variant, Gamma variant, Delta variant and the Omicron variant.
- Conditions
- COVID-19 Pandemic, Immunogenicity, SARS CoV 2 Infection, COVID-19
- Trial name
- SH-MO-214 (NCT05383560)
- Testing
- mRNA-1273.214 Vaccine, MRNA-1273 Vaccine, MRNA-1273.222 Vaccine
- Where
- Israel
- Volunteers
- 179 people, healthy volunteers welcome
- Sponsor
- Sheba Medical Center
SARS-COV 2, Covid19
Pilot Study to Evaluate the Safety, Tolerability, and Efficacy of 5-ALA-Phosphate + SFC as an Immune System Enhancer Along With Vaccination Against COVID-19
This is an open-label, two arm interventional exploratory study to evaluate the safety and efficacy of 5-ALA-Phosphate-SFC during the vaccination of subjects against SARS-CoV-2 (COVID-19) virus infection to define the safety and…
- Trial name
- NCT04854876
- Testing
- 5-ALA-Phosphate + SFC (5-ALA+SFC)
- Volunteers
- healthy volunteers welcome
- Sponsor
- Royal College of Surgeons in Ireland - Medical University of Bahrain
SARS CoV 2 Infection, COVID-19
Sars-COV-2 (COVID-19) Immunity in immunoCOmpromised Populations
The immune response of COVID-19 vaccination was monitored and studied in the context of the previously PICOV study (P2020/424), Nephro- VAC studies (P2020/284 and P2020/312) and Lung-VAC study (P2021/182).
- Trial name
- COVICO (NCT05667597)
- Testing
- Humoral immunity
- Where
- Belgium
- Volunteers
- 350 people, healthy volunteers welcome
- Sponsor
- Maria Goossens
SARS CoV 2 Infection
Study to Evaluate the Safety & Immunogenicity of IMNN-101 Administered in Healthy Adults Previously Vaccinated Against SARS-CoV-2
This is an open-label phase 1/2, dose-escalation study. Participants will receive a single intramuscular (IM) dose of IMNN-101 on Day 0 in the deltoid muscle and will be followed through 12 months post-vaccination (through Study…
- Trial name
- NCT06283459
- Testing
- IMNN-101
- Where
- 2 sites in United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Imunon
Covid19, Corona Virus Infection
Prevalence and Risk Factors of SARS-CoV-2 Antibody Responses (COVID-19)
Observational and prospective study with one year of follow-up of the cohort of workers of the CSdM, including workers of subcontracted companies working in the Hospital of Mataró (2,300 workers approximately) and with controls…
- Conditions
- Covid19, Corona Virus Infection, SARS-CoV 2, COVID
- Trial name
- SERO-MARES (NCT04425759)
- Testing
- Blood sample
- Where
- Spain
- Volunteers
- 2,400 people, healthy volunteers welcome
- Sponsor
- Hospital de Mataró
SARS-CoV 2, COVID-19
COVID-19: Longitudinal Study of Seroprevalence of SARS-CoV-2 Antibodies and Development of Immunity in School Children
There is a lack of knowledge about how many children are infected with SARS-CoV-2, how often they are asymptomatic, and how long the immunity persists.
- Trial name
- CiaoCorona (NCT04448717)
- Testing
- COVID-19 Antibody testing
- Where
- Switzerland
- Volunteers
- 4,250 people, healthy volunteers welcome
- Sponsor
- University of Zurich
SARS-CoV 2, COVID-19
Assessment of the Psycho-social Impact of COVID-19 Outbreak
It has been shown in previous important outbreaks of infectious diseases that they have a huge impact on individuals and communities.
- Conditions
- SARS-CoV 2, COVID-19, Quality of Life, Mental Health Wellness 1
- Trial name
- COM-COVID (NCT04378452)
- Testing
- COM-COVID anonimous survey
- Where
- 4 sites in Spain
- Volunteers
- 56,656 people, healthy volunteers welcome
- Sponsor
- Fundació Institut Germans Trias i Pujol
SARS-CoV 2
SARS-CoV2 (COVID-19) Diagnosis in Human Saliva by MALDI-TOF MS Profiling
Since March 2020, SARS-CoV2 virus (nCoV19; COVID-19) is considered pandemic. Its high rate of spread and infection in the human population and the lack of effective and validated treatment have led the authorities of several…
- Trial name
- CoviDiagMS (NCT04460638)
- Testing
- Saliva collection, Clinical assessment
- Where
- France
- Volunteers
- 779 people, healthy volunteers welcome
- Sponsor
- Direction Centrale du Service de Santé des Armées
COVID, SARS-CoV 2
COVID-19: Herd Immunity Study in the Czech Republic
The aim of the SARS-CoV-2-CZ-Preval study is to quantify the prevalence of individuals with a history of SARS-CoV-2 coronavirus infection in the Czech population, except for those diagnosed with COVID-19 by methods based on…
- Trial name
- SARSCoV2CZPrev (NCT04401085)
- Testing
- SARS-CoV-2 diagnostic rapid test, Quantitative analysis of SARS-CoV-2 antibodies
- Where
- Czechia
- Volunteers
- 27,000 people, healthy volunteers welcome
- Sponsor
- Institute of Health Information and Statistics of the Czech Republic
COVID-19, Coronavirus
Will Hydroxychloroquine Impede or Prevent COVID-19
This is a prospective, multi-site study designed to evaluate whether the use of hydroxychloroquine in healthcare workers (HCW), Nursing Home Workers (NHW), first responders (FR), and Detroit Department of Transportation bus…
- Conditions
- COVID-19, Coronavirus, Coronavirus Infections, SARS-CoV 2
- Trial name
- WHIP COVID-19 (NCT04341441)
- Testing
- Hydroxychloroquine - Daily Dosing, Hydroxychloroquine - Weekly Dosing, Monitoring Visit - Baseline
- Where
- United States
- Volunteers
- 624 people, healthy volunteers welcome
- Sponsor
- Henry Ford Health System
COVID-19, Coronavirus Infection
Efficacy of Oral Rinses for Inactivation of COVID-19 (MOR2)
Randomized, double-blind prospective trial to test the efficacy of therapeutic, antiseptic mouth rinses to inactivate severe acute respiratory syndrome coronavirus (SARS-CoV-2) in saliva of COVID-19 positive patients aged 18-65…
- Conditions
- COVID-19, Coronavirus Infection, SARS CoV 2 Infection
- Trial name
- MOR2 (NCT05178173)
- Testing
- 27% Ethanol plus essential oils, 0.075% Cetylpyridinium Chloride
- Where
- United States
- Volunteers
- 230 people, healthy volunteers welcome
- Sponsor
- University of North Carolina, Chapel Hill
SARS CoV 2 Vaccination
Impact of COVID-19 Vaccination on Balance Function Among Adolescents: A Long-Term Perspective
Long term impact of COVID 19 vaccination on dizziness-related disability and balance in adolescence
- Trial name
- NCT06503926
- Testing
- SARS-COV-2 vaccination
- Where
- Egypt
- Volunteers
- 270 people, healthy volunteers welcome
- Sponsor
- Sinai University
COVID-19, Vaccine-Preventable Diseases
Impact of Reactogenicity of the 2024-2025 COVID-19 Vaccines on Health Care Workers and First Responders in the United States
To assess the impact of reactogenicity among health care workers and first responders receiving an updated 2024-25 Novavax COVID-19 vaccine as compared with those receiving an updated 2024-25 Pfizer-BioNTech mRNA COVID-19 vaccine
- Conditions
- COVID-19, Vaccine-Preventable Diseases, SARS CoV 2 Infection
- Trial name
- SHIELD (NCT06633835)
- Testing
- protein subunit: Novavax COVID-19 vaccine, Pfizer mRNA COVID-19 vaccine
- Where
- United States
- Volunteers
- 660 people, healthy volunteers welcome
- Sponsor
- Novavax
SARS-CoV 2, COVID-19
Seroprevalence of SARS CoV 2 Antibodies in Previously Undiagnosed Healthcare Workers
The purpose of this study is to identify healthcare workers with SARS CoV 2 antibodies who have not been previously diagnosed and are presumed COVID-19 negative, then determine the level of immunity in this population which could…
- Trial name
- NCT04383587
- Testing
- Serologic testing
- Where
- United States
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
COVID-19 Prevention
Safety, Tolerability, and Pharmacokinetics of Q-Griffithsin Intranasal Spray
The purpose of this study is to test the safety of multiple doses of a Q-GRFT nasal spray in healthy volunteers. This Q-GRFT nasal spray is "investigational and not approved by the FDA for general use" and is being developed to…
- Trial name
- NCT05437029
- Testing
- Q-Griffithsin 3.0, Q-Griffithsin 6.0
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Kenneth Palmer
SARS CoV 2 Infection, Influenza A Virus Infection
Clinical Validation of the NowFuture Digital Flu / COVID Test in Anterior Nasal Samples for Over-the-Counter (OTC) Use in Australia
Prospective clinical study conducted at three sites (with a simulated home environment) in Australia for the clinical validation of the NowFuture Digital Flu / COVID Test.
- Conditions
- SARS CoV 2 Infection, Influenza A Virus Infection, Influenza B Virus Infection
- Trial name
- NCT07743970
- Testing
- Diagnostic test for SARS-CoV-2, influenza A and influenza B
- Where
- 3 sites in Australia
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Biocrucible Ltd